Nascent Biotech, Inc.
NBIO · OTC
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.31 | -0.01 | 0.20 | 0.05 |
| FCF Yield | -4.23% | -26.80% | 6.73% | -22.00% |
| EV / EBITDA | 52.68 | -6.42 | 360.30 | -7.71 |
| Quality | ||||
| ROIC | 1,662.02% | 237.83% | 68.06% | 450.50% |
| Gross Margin | 0.00% | 0.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.57 | 0.64 | -0.88 | 1.03 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | – | – |
| Free Cash Flow Growth | 33.64% | -532.24% | 141.90% | -78.02% |
| Safety | ||||
| Net Debt / EBITDA | -0.47 | -0.20 | -5.63 | -0.27 |
| Interest Coverage | -5.79 | -1.25 | -0.94 | -3.93 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -784.01 | 0.00 | 0.00 | 365.00 |